Experimental Drug May Lower Heart Attack Risk by 50 Percent

A new experimental drug has had the effect of lowering the likelihood of heart attack, stroke and death in patients receiving treatment for high cholesterol. The biologic drug evolocumab has decreased the likelihood of adverse health problems by 50 percent in test subjects compared to those receiving solely conventional treatment for high cholesterol. Evolocumab works in conjunction with traditional high cholesterol treatments, like statins, by blocking a protein in the liver which reduces the liver’s ability to remove LDL, known as “bad cholesterols.”

Statins will always be the foundation of therapy. These [new drugs] will be an additional medicine for patients who aren’t getting appropriate control of their cholesterol on a statin alone,”

The study was published in the New England Journal of Medicine. The study was led by senior cardiologist at the Brigham and Women’s Hospital by Dr. Marc Sabine and funded by the drug’s maker, Amgen.

Evolocumab is one of what is likely to be many biologic drugs that seek to be allowed into the US market. The Food and Drug Administrations is reviewing biologic drugs as a class to see if they are safe and effective.


Read More – Drug May Lower Cholesterol, Heart Attack Risk (WebMD, Kathleen Doheny)

+ posts

Originally from Gaithersburg, Maryland, Millan is a senior at the George Washington University studying Biological Anthropology.



Subscribe to get the latest consumer news

More consumer News